EGFR and neoplasm: Examples include monoclonal antibodies such as cetuximab (Erbitux) and panitumumab (Vectibix) that target epidermal growth factor receptor (EGFR), immune checkpoint inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) [8,9], and agents targeting vascular endothelial growth factor (VEGFR) signalling to disrupt tumour vascularisation such as bevacizumab (Avastin) and ramucirumab (Cyramza) [10].